Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of The Andelyn Foundation, a nonprofit ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

Parent Project Muscular Dystrophy (PPMD), in partnership with the Foundation to Eradicate Duchenne (FED), today announced Representative Troy Balderson (OH-12), Senator Susan Collins (ME), Senator Amy ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

Columnist Patrick Moeschen recalls how he worried about falling behind classmates in the years before his MD diagnosis.

Four patients with LGMD-R5 (gamma-sarcoglycanopathy, formerly LGMD-2C) have received the ATA-200 gene therapy as part of the ongoing Phase 1b/2 trial evaluating the safety, pharmacodynamics, and ...

Through the support of the Jett Foundation, the Criado family is working to raise funds for an accessible vehicle that could ...

Luke Criado's family is working to raise money for a wheel-chair accessible vehicle. For years he's contended with a muscle ...

Families affected by the condition and a dedicated support crew walked 92km across Perth over four days to raise funds and ...

This Monday 9 March, the nation is invited to celebrate National Meatball Day with purpose, by turning its love of meatballs ...

The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop ...

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...